Economic impact of genomic diagnostics for intermediate‐risk acute myeloid leukaemia by Cressman, S, Karsan, A, Hogge, DE, McPherson, E, Bolbocean, C, Regier, DA, Peacock, SJ

Senior Hospital Physician Leaders’ Perspectives on Factors That Impact Physician Engagement: A Qualitative Interview Study by Simard J, Shea C, Cho V, Perrier L, Prokopy M, Moshirzadeh E, Sodhi S, Karsan A, Perreira TA

Get full text

SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS by Malcovati, L, Stevenson, K, Papaemmanuil, E, Neuberg, D, Bejar, R, Boultwood, J, Bowen, DT, Campbell, PJ, Ebert, BL, Fenaux, P, Haferlach, T, Heuser, M, Jansen, JH, Komrokji, RS, Maciejewski, JP, Walter, MJ, Fontenay, M, Garcia-Manero, G, Graubert, TA, Karsan, A, Meggendorfer, M, Pellagatti, A, Sallman, DA, Savona, MR, Sekeres, M, Steensma, DP, Tauro, S, Thol, F, Vyas, P, Van de Loosdrecht, AA, Haase, DT, Tuechler, H, Greenberg, PL, Ogawa, S, Hellstrom-Lindberg, ES, Cazzola, M

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups by Haase, D, Stevenson, KE, Neuberg, D, Maciejewski, JP, Nazha, A, Sekeres, MA, Ebert, BL, Garcia-Manero, G, Haferlach, C, Haferlach, T, Kern, W, Ogawa, S, Nagata, Y, Yoshida, K, Graubert, TA, Walter, MJ, List, AF, Komrokji, RS, Padron, E, Sallman, D, Papaemmanuil, E, Campbell, PJ, Savona, MR, Seegmiller, A, Adès, L, Fenaux, P, Shih, L-Y, Bowen, D, Groves, MJ, Tauro, S, Fontenay, M, Kosmider, O, Bar-Natan, M, Steensma, D, Stone, R, Heuser, M, Thol, F, Cazzola, M, Malcovati, L, Karsan, A, Ganster, C, Hellström-Lindberg, E, Boultwood, J, Pellagatti, A, Santini, V, Quek, L, Vyas, P, Tüchler, H, Greenberg, PL, Bejar, R, International Working Group For Mds Molecular Prognostic Committee